Preclinical and First‐In‐Human Evaluation of Ribupatide ( HRS9531 ), a Dual GLP ‐1/ GIP Receptor Agonist
Diabetes, Obesity and Metabolism · 2026-12 · 28 (12) · 11643-11652
DOI: 10.1111/dom.71218 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 20.09.2026. Verfasst von Kun He und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Research Centre, Central Hospital Affiliated to Shandong First Medical University, Jinan, China. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Obesity, Receptors, Gastrointestinal Hormone. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Jiangsu Hengrui Pharmaceuticals Co. Ltd.
Abstract (Originalsprache)
Aims
This study assessed the preclinical and clinical pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of ribupatide (HRS9531), a novel dual agonist of glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) receptors.
Methods
Preclinical assessments of ribupatide included in vitro functional receptor potency assays, PK evaluations in Sprague–Dawley (SD) rats and cynomolgus monkeys and PD assessments in diet‐induced obese (DIO) mice. The Phase 1 study comprised single‐ascending dose (SAD; 0.1, 0.3, 0.9, 2.7, 5.4 and 8.1 mg) and multiple‐ascending dose (MAD; 0.9, 2.7 and 5.4 mg [2.7/2.7/4.0/5.4 mg]) parts. In the MAD part, ribupatide or placebo was administered subcutaneously once weekly for 4 weeks. The primary endpoints were safety and tolerability.
Results
Ribupatide is a chemically synthesised polypeptide that activates both GLP‐1 and GIP receptor signalling pathways in vitro. In SD rats and cynomolgus monkeys, ribupatide demonstrated good subcutaneous bioavailability. In DIO mice, it significantly reduced body weight and cumulative food intake over 28 days compared with vehicle‐treated controls. These preclinical PK/PD findings provided a rationale for clinical studies. A total of 90 healthy Chinese participants were randomised and received study treatment, of whom 87 (96.7%) completed the study. Ribupatide was well tolerated across all dose levels, with all treatment‐emergent adverse events (TEAEs) being mild‐to‐moderate in severity and no serious TEAEs or deaths reported. In the MAD, the mean half‐life was 7–8 days across the dose range. Fasting plasma glucose decreased dose‐dependently after single and multiple dosing. After four weekly doses, mean weight change in ribupatide groups ranged from −4.3 kg (−6.7%) to −7.7 kg (−9.6%), compared with −1.2 kg (−1.4%) in the placebo group.
Conclusions
Ribupatide exhibited a favourable safety and tolerability profile, along with PK properties consistent with once‐weekly administration. Its glucose‐lowering and weight‐loss effects support further clinical development for the treatment of type 2 diabetes mellitus and obesity. Trial Registration: ClinicalTrials.gov identifier: NCT05152277.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Research Centre, Central Hospital Affiliated to Shandong First Medical University, Jinan, China.
- Global Research and Development, Jiangsu Hengrui Pharmaceuticals Co. Ltd, Shanghai, China.
- Department of Peptide Chemistry, Jiangsu Hengrui Pharmaceuticals Co. Ltd, Shanghai, China.
- Department of Clinical Pharmacology, Jiangsu Hengrui Pharmaceuticals Co. Ltd, Shanghai, China.
- Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co. Ltd, Shanghai, China.
- Nonclinical Development, Jiangsu Hengrui Pharmaceuticals Co. Ltd, Shanghai, China.
ORCID-Profile: Qing Wen
Förderung
- Jiangsu Hengrui Pharmaceuticals Co. Ltd
Zitieren
APA
He, K., Wei, Y., Zhao, H., Zhang, L., Wu, F., Liu, R., Zhang, Y., Wang, Y., Chen, H., Zeng, M., Zhi, L., Zhou, T., Sheng, Z., & Wen, Q. (2026). Preclinical and First‐In‐Human Evaluation of Ribupatide ( HRS9531 ), a Dual GLP ‐1/ GIP Receptor Agonist. Diabetes, Obesity and Metabolism, 28(12), 11643-11652. https://doi.org/10.1111/dom.71218
Vancouver
He K, Wei Y, Zhao H, Zhang L, Wu F, Liu R, et al. Preclinical and First‐In‐Human Evaluation of Ribupatide ( HRS9531 ), a Dual GLP ‐1/ GIP Receptor Agonist. Diabetes, Obesity and Metabolism. 2026;28(12):11643-11652. doi:10.1111/dom.71218
BibTeX
@article{He2026,
author = {He, Kun and Wei, Yilin and Zhao, Hengli and Zhang, Lianshan and Wu, Fangzhou and Liu, Renzhi and Zhang, Yanyan and Wang, Yike and Chen, Hong and Zeng, Meifang and Zhi, Li and Zhou, Tianlin and Sheng, Zhen and Wen, Qing},
title = {Preclinical and First‐In‐Human Evaluation of Ribupatide ( HRS9531 ), a Dual GLP ‐1/ GIP Receptor Agonist},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {12},
pages = {11643--11652},
doi = {10.1111/dom.71218}
}
EUVIMED